Screener
Sana Biotechnology SANA Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $83,800 | $71,870 |
| Marketable securities | 17,336 | 66,512 |
| Restricted cash | 4,195 | 4,195 |
| Prepaid expenses and other current assets | 6,359 | 6,099 |
| Total current assets | 111,690 | 148,676 |
| Property and equipment, net | 25,673 | 26,906 |
| Operating lease right-of-use assets | 35,845 | 38,313 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's restricted cash?
- Sana Biotechnology (SANA) reported restricted cash of $4.2M in Q1 2026.
- How has Sana Biotechnology's restricted cash changed year-over-year?
- Sana Biotechnology's restricted cash decreased by 0.0% year-over-year, from $4.2M to $4.2M.
- What is the long-term trend for Sana Biotechnology's restricted cash?
- Over 5 years (2020 to 2025), Sana Biotechnology's restricted cash has grown at a 14.4% compound annual growth rate (CAGR), from $2.14M to $4.2M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Sana Biotechnology's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude